ATE324913T1 - Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens - Google Patents

Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens

Info

Publication number
ATE324913T1
ATE324913T1 AT99939113T AT99939113T ATE324913T1 AT E324913 T1 ATE324913 T1 AT E324913T1 AT 99939113 T AT99939113 T AT 99939113T AT 99939113 T AT99939113 T AT 99939113T AT E324913 T1 ATE324913 T1 AT E324913T1
Authority
AT
Austria
Prior art keywords
plasmid
complex
nucleic acid
acid vector
formulation agent
Prior art date
Application number
AT99939113T
Other languages
English (en)
Inventor
Maria Bruno
Jenna Tagliaferri
Luke Lawson
Mark J Logan
Russ Mumper
Original Assignee
Valentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc filed Critical Valentis Inc
Application granted granted Critical
Publication of ATE324913T1 publication Critical patent/ATE324913T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/789—Of specified organic or carbon-based composition in array format
    • Y10S977/79—Of specified organic or carbon-based composition in array format with heterogeneous nanostructures
    • Y10S977/791—Molecular array
    • Y10S977/792—Nucleic acid array, e.g. human genome array
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/80—Nucleic acid, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
AT99939113T 1998-08-14 1999-08-10 Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens ATE324913T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9657298P 1998-08-14 1998-08-14

Publications (1)

Publication Number Publication Date
ATE324913T1 true ATE324913T1 (de) 2006-06-15

Family

ID=22258010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99939113T ATE324913T1 (de) 1998-08-14 1999-08-10 Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens

Country Status (8)

Country Link
US (1) US6534483B1 (de)
EP (1) EP1104309B8 (de)
JP (1) JP4538150B2 (de)
AT (1) ATE324913T1 (de)
AU (1) AU5345999A (de)
CA (1) CA2340416C (de)
DE (1) DE69931166T2 (de)
WO (1) WO2000009086A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426582A1 (en) * 2000-10-20 2002-08-08 Valentis, Inc. Gene delivery formulations and methods for treatment of ischemic conditions
WO2003086494A1 (en) * 2002-04-05 2003-10-23 Baxter International Inc. Storage stable liquid sealer protein complex
WO2004092201A2 (en) * 2003-03-31 2004-10-28 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced hiv-1 vaccines and methods for their use
WO2005113147A2 (en) * 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
CA2566199C (en) * 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
EP1765294B1 (de) * 2004-05-12 2008-09-24 Baxter International Inc. Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US20060003308A1 (en) * 2004-05-12 2006-01-05 Bio-Rad Laboratories, Inc. Electrocompetent cells prepackaged for electroporation
JP4820979B2 (ja) * 2004-10-12 2011-11-24 国立大学法人広島大学 細胞培養装置
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
RU2010116775A (ru) 2007-09-28 2011-11-10 Энджин, Инк. (Ca) Высококонцентрированные композиции полиплекса хитозана и нуклеиновой кислоты
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
EP2440251A4 (de) * 2009-06-09 2013-01-16 Defyrus Inc Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (de) 2010-07-26 2017-03-15 Biomatrica, INC. Zusammensetzungen zur stabilisierung von dna, rna und proteinen in blut- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen
KR101507254B1 (ko) * 2010-12-07 2015-03-30 에프. 호프만-라 로슈 아게 공급물 혼합 장치 및 그 용도
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US12064484B2 (en) * 2013-06-28 2024-08-20 Ethris Gmbh Compositions for introducing RNA into cells
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
WO2016075154A1 (en) 2014-11-10 2016-05-19 Ethris Gmbh Induction of osteogenesis by delivering bmp encoding rna
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CA3205588A1 (en) * 2020-12-21 2022-06-30 Pfizer Inc. Methods and systems for improved cell transfection
WO2023064187A1 (en) * 2021-10-13 2023-04-20 Life Technologies Corporation Scalable systems and methods for continuous transfection of cells
WO2023164259A1 (en) * 2022-02-28 2023-08-31 Corning Incorporated Methods and systems for real-time, continuous production of non-viral carrier nucleic acid particles

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5164598A (en) * 1985-08-05 1992-11-17 Biotrack Capillary flow device
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
US5738898A (en) * 1995-03-31 1998-04-14 Board Of Trustees Operating Michigan State University Process for reducing sterols in eggs
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
US5686071A (en) 1995-06-06 1997-11-11 Per Immune Holdings, Inc. Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US5763158A (en) * 1997-02-06 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Detection of multiple antigens or antibodies
US6303378B1 (en) 1997-10-24 2001-10-16 Valentis, Inc. Methods for preparing polynucleotide transfection complexes
WO1999040771A2 (en) 1998-02-13 1999-08-19 Selective Genetics, Inc. Concurrent flow mixing for preparing compositions comprising gene therapy vectors
PT1061955E (pt) * 1998-03-13 2005-08-31 Wyeth Corp Composicao de polinucleotido, metodo de preparacao e sua utilizacao

Also Published As

Publication number Publication date
JP2002522468A (ja) 2002-07-23
DE69931166D1 (de) 2006-06-08
WO2000009086A3 (en) 2000-06-08
US6534483B1 (en) 2003-03-18
CA2340416A1 (en) 2000-02-24
CA2340416C (en) 2009-06-02
AU5345999A (en) 2000-03-06
EP1104309B1 (de) 2006-05-03
DE69931166T2 (de) 2007-02-15
JP4538150B2 (ja) 2010-09-08
WO2000009086A2 (en) 2000-02-24
EP1104309A2 (de) 2001-06-06
EP1104309B8 (de) 2006-07-05

Similar Documents

Publication Publication Date Title
ATE324913T1 (de) Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens
WO2004084950A3 (en) Cell targeting methods and compositions
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
TR199701071T2 (xx) Aktif madde ula�t�rmaya mahsus bile�ikler ve terkipler.
EP1283054A4 (de) Medikamente zur behandlung von komplikationen des diabetes und neuropathien, und verwendung davon
IL140710A0 (en) Pulmonary delivery of active agents
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
ATE329586T1 (de) Zusammensetzungen enthaltend carotenoide und deren verwendung zur verhinderung hormon- induzierter nebenwirkungen
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
WO2005084180A3 (en) Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
BG106046A (en) Pharmaceutical compositions of ertythropoietin
WO2003018059A3 (de) Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
WO2019147743A8 (en) Structure-guided chemical modification of guide rna and its applications
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
TW200510344A (en) Aryl-heteroaromatic products, compositions comprising them and use
AU2002340670A1 (en) Lipid carrier compositions and methods for improved drug retention
ATE456951T1 (de) Antitumorale mittel und verfahren zu ihrer herstellung
CA2359491A1 (en) Mixture of plant treatment compositions with waxes, their preparation, and their use
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
WO2004043993A3 (fr) Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
ATE408619T1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
PL353209A1 (en) Paracetamol and drotaverine containing composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1104309

Country of ref document: EP